Form: 8-K

Current report filing

July 21, 2023

Documents

0001335105 false 0001335105 2023-07-20 2023-07-20 0001335105 LIXT:CommonStockParValue0.0001PerShareMember 2023-07-20 2023-07-20 0001335105 LIXT:WarrantToPurchaseCommonStockParValue0.0001PerShareMember 2023-07-20 2023-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 20, 2023

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

delaware   001-39717   20-2903526
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   LIXT   The Nasdaq Stock Market, LLC
Warrant to Purchase Common Stock, par value $0.0001 per share   LIXTW   The Nasdaq Stock Market, LLC

 

 

 

 

 

 

Item 8.01. Other Events.

 

Reference is made to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 20, 2023 in connection with the Registered Offering. The Registered Offering closed on July 20, 2023. The Company issued a press release with respect to the closing of the Registered Offering on July 20, 2023. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) There are filed as part of this report the exhibits listed on the accompanying Index to Exhibits which exhibit is incorporated herein by reference.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 21, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
   
  By: /s/ JOHN S. KOVACH
    John S. Kovach,
    Chief Executive Officer

 

3

 

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
99.1   Press Release dated July 20, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

4